p r 2 - MassPharma(Private)Limited CHAPTER No.1...

Info iconThis preview shows pages 1–4. Sign up to view the full content.

View Full Document Right Arrow Icon
  Mass Pharma (Private) Limited CHAPTER No.1 INTRODUCTION OF PRODUCT GLIP is a product of Mass Pharma Company. Mass Pharma (Pvt.) Limited is situated in the historical city of Lahore and very proudly claims to be one of the most professionally designed pharmaceutical industry of Pakistan. Mass Pharma started its operation in 1998. The company has emerged as one of the fastest growing companies among the Pharma industry of Pakistan by manufacturing quality products of international standards which have been ac- knowledged by the Health Care Professionals all over the country and can be very rightly said that Mass Pharma is among one of the leading pharmaceutic- al quality conscious companies. GLIP: (Product which we Re-launch) Fig 1.1(GLIP) GLIP (Glipmepiride) is approved for once daily use as monotherapy or in com- bination with insulin. Glimepiride achieves blood glucose lowering with the lowest dose of any sulphonylurea compound. A single daily dose of 1 mg has been shown to be effective and the recommended maximal daily dose is 8 mg. It has a long duration of action with a half life of 5 hour, allowing once daily (Glimipride) Referred sometimes as a third generation Sulphonyl Urea Mode of Action 1
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
  Mass Pharma (Private) Limited GLIP work at the cellular level to stimulate the release of insulin from the pancreas. GLIP effects on beta cells of pancreas GLIP effect at target tissues outside the pancreas GLIP seems to stimulate insulin production primarily after meals, when glucose levels are highest, but the drug provide glucose control throughout the day Older SU’s may cause hyperinsulinemia Hyperinsulinemia can promote weight gain and increase risk of hy- poglycemia Binding to K-ATP channels, causing Opening of Ca channel which Simulates insulin release Pharmacokinetics The Pharmacokinetics effect of GLIP do not vary with age or gender Absorption GLIP is completely absorbed after oral administration GLIP remains in blood circulation and extra cellular fluid Highly protein binding 99.5% The binding is weak, therefore it easily moves from plasma protein to the cell surface receptor Metabolites of GLIP have little or no biological activity GLIP has other effects on the body that affect diabetes therapy Indications GLIP decrease blood glucose by: Increasing Glycogen synthesis (by increasing activity of glycogen syn- thase) 2
Background image of page 2
Mass Pharma (Private) Limited Increase Glut 4 transporters at cell surfaces No effect on plasma lipid levels Where every blood sugar level cannot be controlled adequately by: Diet Physical Exercise Weight Reduction (Glimepride) Opening Doctor, in the treatment of type II Diabetes Mel- litus your main concern is to control fasting plasma glucose level and random Plasma Gluc- ose level Moreover according to UKPDS HbA1c level are very important in the tight control of dia-
Background image of page 3

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Image of page 4
This is the end of the preview. Sign up to access the rest of the document.

This note was uploaded on 05/25/2011 for the course MGMT 46 taught by Professor Tariqrafiq during the Fall '11 term at COMSATS Institute Of Information Technology.

Page1 / 32

p r 2 - MassPharma(Private)Limited CHAPTER No.1...

This preview shows document pages 1 - 4. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online